Evaluating Value of BTK Inhibitors in CLL Treatment

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment efficacy, and more.

Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).